BiotechTube

0.03% E6201 + 0.1% E6201 + 0.2% E6201 + 0.005% E6201 + 0.01% E6201 + 0.05% E6201 + Calcipotriene

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis Vulgaris

Conditions

Psoriasis Vulgaris

Trial Timeline

Mar 15, 2010 → Dec 11, 2010

NCT ID
NCT01268527

About 0.03% E6201 + 0.1% E6201 + 0.2% E6201 + 0.005% E6201 + 0.01% E6201 + 0.05% E6201 + Calcipotriene

0.03% E6201 + 0.1% E6201 + 0.2% E6201 + 0.005% E6201 + 0.01% E6201 + 0.05% E6201 + Calcipotriene is a phase 2 stage product being developed by Eisai for Psoriasis Vulgaris. The current trial status is completed. This product is registered under clinical trial identifier NCT01268527. Target conditions include Psoriasis Vulgaris.

What happened to similar drugs?

20 of 20 similar drugs in Psoriasis Vulgaris were approved

Approved (20) Terminated (3) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Ilumya Injectable ProductSun PharmaceuticalApproved
✅TildrakizumabSun PharmaceuticalApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01268527Phase 2Completed

Competing Products

20 competing products in Psoriasis Vulgaris

See all competitors
ProductCompanyStageHype Score
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + PlaceboDr. Reddy's LaboratoriesPhase 2
32
Ixekizumab + PlaceboEli LillyPhase 2
35
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
21
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
27
IxekizumabEli LillyPhase 3
40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
40
Placebo + BaricitinibEli LillyPhase 2
35
CT-P43 + StelaraCelltrionPhase 3
40
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
AMG 139AstraZenecaPhase 1
29
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 2
35
Tacrolimus CreamAstellas PharmaPhase 3
40
alefaceptAstellas PharmaPhase 3
40
peficitinib + PlaceboAstellas PharmaPhase 2
35
AlefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40